177 related articles for article (PubMed ID: 36018224)
1. Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years.
Elalfy MS; Hamdy M; El-Beshlawy A; Ebeid FSE; Badr M; Kanter J; Inusa B; Adly AAM; Williams S; Kilinc Y; Lee D; Fradette C; Rozova A; Temin NT; Tricta F; Kwiatkowski JL
Blood Adv; 2023 Feb; 7(4):611-619. PubMed ID: 36018224
[TBL] [Abstract][Full Text] [Related]
2. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.
Kwiatkowski JL; Hamdy M; El-Beshlawy A; Ebeid FSE; Badr M; Alshehri A; Kanter J; Inusa B; Adly AAM; Williams S; Kilinc Y; Lee D; Tricta F; Elalfy MS
Blood Adv; 2022 Feb; 6(4):1243-1254. PubMed ID: 34847228
[TBL] [Abstract][Full Text] [Related]
3. Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study.
Hamdy M; El-Beshlawy A; Veríssimo MPA; Kanter J; Inusa B; Williams S; Lee D; Temin NT; Fradette C; Tricta F; Ebeid FSE; Kwiatkowski JL; Elalfy MS
Pediatr Blood Cancer; 2024 Jan; 71(1):e30711. PubMed ID: 37807937
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
[TBL] [Abstract][Full Text] [Related]
5. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
Cochrane Database Syst Rev; 2013 Aug; (8):CD004450. PubMed ID: 23963793
[TBL] [Abstract][Full Text] [Related]
6. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
Meerpohl JJ; Antes G; Rücker G; Fleeman N; Niemeyer C; Bassler D
Cochrane Database Syst Rev; 2010 Aug; (8):CD007477. PubMed ID: 20687088
[TBL] [Abstract][Full Text] [Related]
7. Real-world evidence: Long-term safety of deferiprone in a large cohort of patients with sickle cell disease enrolled in a registry for up to 10 years.
Kwiatkowski JL; Thompson AA; Tricta F; Temin NT; Rozova A; Fradette C; Badawy SM
Am J Hematol; 2024 Jun; 99(6):1031-1039. PubMed ID: 38429922
[TBL] [Abstract][Full Text] [Related]
8. Oral deferiprone for iron chelation in people with thalassaemia.
Fisher SA; Brunskill SJ; Doree C; Chowdhury O; Gooding S; Roberts DJ
Cochrane Database Syst Rev; 2013 Aug; (8):CD004839. PubMed ID: 23966105
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease.
Soulières D; Mercier-Ross J; Fradette C; Rozova A; Tsang YC; Tricta F
Ann Hematol; 2022 Mar; 101(3):533-539. PubMed ID: 34981144
[TBL] [Abstract][Full Text] [Related]
10. Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial.
Calvaruso G; Vitrano A; Di Maggio R; Ballas S; Steinberg MH; Rigano P; Sacco M; Telfer P; Renda D; Barone R; Maggio A;
Blood Cells Mol Dis; 2014 Dec; 53(4):265-71. PubMed ID: 24814618
[TBL] [Abstract][Full Text] [Related]
11. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
Kolnagou A; Kleanthous M; Kontoghiorghes GJ
Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
Taher A; El-Beshlawy A; Elalfy MS; Al Zir K; Daar S; Habr D; Kriemler-Krahn U; Hmissi A; Al Jefri A
Eur J Haematol; 2009 Jun; 82(6):458-65. PubMed ID: 19187278
[TBL] [Abstract][Full Text] [Related]
13. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
Viprakasit V; Nuchprayoon I; Chuansumrit A; Torcharus K; Pongtanakul B; Laothamatas J; Srichairatanakool S; Pooliam J; Supajitkasem S; Suriyaphol P; Tanphaichitr VS; Tuchinda S
Am J Hematol; 2013 Apr; 88(4):251-60. PubMed ID: 23460233
[TBL] [Abstract][Full Text] [Related]
14. Deferiprone as an oral iron chelator in sickle cell disease.
Voskaridou E; Douskou M; Terpos E; Stamoulakatou A; Meletis J; Ourailidis A; Papassotiriou I; Loukopoulos D
Ann Hematol; 2005 Jul; 84(7):434-40. PubMed ID: 15809885
[TBL] [Abstract][Full Text] [Related]
15. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.
ElAlfy MS; Sari TT; Lee CL; Tricta F; El-Beshlawy A
J Pediatr Hematol Oncol; 2010 Nov; 32(8):601-5. PubMed ID: 20921906
[TBL] [Abstract][Full Text] [Related]
16. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
[TBL] [Abstract][Full Text] [Related]
18. Assessing cardiac and liver iron overload in chronically transfused patients with sickle cell disease.
Badawy SM; Liem RI; Rigsby CK; Labotka RJ; DeFreitas RA; Thompson AA
Br J Haematol; 2016 Nov; 175(4):705-713. PubMed ID: 27507431
[TBL] [Abstract][Full Text] [Related]
19. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients.
Hoffbrand AV; AL-Refaie F; Davis B; Siritanakatkul N; Jackson BF; Cochrane J; Prescott E; Wonke B
Blood; 1998 Jan; 91(1):295-300. PubMed ID: 9414297
[TBL] [Abstract][Full Text] [Related]
20. Deferiprone exerts a dose-dependent reduction of liver iron in adults with iron overload.
Binding A; Ward R; Tomlinson G; Kuo KHM
Eur J Haematol; 2019 Aug; 103(2):80-87. PubMed ID: 31066943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
